A Phase 1 interventional study of Ertugliflozin in Renal Impairment and Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-18.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 5 that started in 2013, is one of 25 in phase 1, and was the 16th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.
Browse Renal Insufficiency studies →2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Merck Sharp & Dohme LLC
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 36 is close to the median of 40 across 1,060 interventional studies indexed under Renal Insufficiency.
Median enrollment 26 across the 32 interventional studies. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
2 of the studies in Renal Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07734610Merck Sharp & Dohme LLCA Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) | 2027-02-01 |
| NCT07922174Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | 2027-08-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the effect of renal impairment on the pharmacokinetics, pharmacodynamics, safety and tolerability of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and in healthy participants with normal renal function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin (15 mg), oral, administered in participants with T2DM and with normal renal function
Drug: Ertugliflozin
Ertugliflozin (15 mg), oral, administered in participants with T2DM and with mild renal impairment
Drug: Ertugliflozin
Ertugliflozin (15 mg), oral, administered in participants with T2DM and with moderate renal impairment
Drug: Ertugliflozin
Ertugliflozin (15 mg), oral, administered in participants with T2DM and with severe renal impairment
Drug: Ertugliflozin
Ertugliflozin (15 mg), oral, administered in participants with healthy participants and with normal renal function
Drug: Ertugliflozin
Single oral administration of 3 X 5 mg tablets.
Also known as: MK-8835
Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf)
Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Apparent Clearance (CL/F) for Plasma Ertugliflozin
CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Time for Cmax (Tmax) for Plasma Ertugliflozin
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Terminal Half-Life (t1/2) for Plasma Ertugliflozin
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Apparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin
VzF is the apparent volume of distribution during terminal phase after oral / extravascular administration. VzF = Dose/(AUCinf × kel) where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Unbound Fraction (Fu) for Plasma Ertugliflozin
Fraction of unbound (not protein-bound) drug in plasma. Fu is determined using in vitro equilibrium dialysis method: concentration in buffer at equilibrium/concentration in plasma at equilibrium. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96)
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Percent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%)
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96% = Ae96 / Dose × 100 Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Renal Clearance (CLr) for Urinary Ertugliflozin
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Number of Participants Who Experienced an Adverse Event (AE)
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 19 days
Number of Participants Who Discontinued Study Due to an AE
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 5 days
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf)
Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06481944
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06481944
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06481944
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
CLr for Urinary Glucuronide Metabolite PF-06481944
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf)
Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06685948
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06685948
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06685948
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.
Time frame: Time 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, and 96 hours post-dose
Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06685948
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Renal Clearance (CLr) for Urinary Glucuronide Metabolite PF-06685948
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
Time frame: 0-4, 4-8, 8-12, 12-24, 24-48, 48-72, and 72-96 hours after dosing on Day 1
Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption
Inhibition of Glucose Reabsorption = 100 \* urinary glucose excretion / (eGFR(ML/MIN) \* Weighted Mean Plasma Glucose \* 0.0144). 0.0144 is a unit conversion factor used to make the ratio unitless. Geometric Coefficient of Variation was reported as a percent.
Time frame: Baseline and 24 Hours
Change From Baseline in 24 Hour Fluid Balance
Fluid balance = fluid intake - urine output.
Time frame: For 24 hours before Baseline (-48 to -24 hours) and up to 24 hours after dosing on Day 1 (Up to 24 hours)
Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin
Participants were asked to void at the end of each prescribed interval with forced voids prior to start and at the end of each interval.
Time frame: 0-4, 4-8, 8-12, 12-24 hours after dosing on Day 1
| Milestone | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Started | 6 | 8 | 8 | 6 | 8 |
| Completed | 6 | 8 | 8 | 6 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
| ng•hr/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 Extrapolated to Infinite Time (AUCinf) | 1199 ± 42 | 1908 ± 28 | 2075 ± 19 | 1895 ± 23 | 1236 ± 27 |
Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
| ng•hr/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile for Ertugliflozin From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) | 1174 ± 42 | 1814 ± 27 | 2011 ± 18 | 1816 ± 23 | 1214 ± 27 |
CL/F is a calculation of the rate at which a drug is removed from the body via renal, hepatic and other clearance pathways, expressed as volume (milliliters) per unit of time (minutes). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
| mL/min | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) for Plasma Ertugliflozin | 208.8 ± 42 | 130.9 ± 28 | 120.4 ± 19 | 132.0 ± 23 | 202.1 ± 27 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
| ng/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Ertugliflozin | 215.9 ± 35 | 313.1 ± 30 | 305.7 ± 23 | 196.4 ± 28 | 219.3 ± 26 |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.
| Hours | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Time for Cmax (Tmax) for Plasma Ertugliflozin | 1.00 (1.00 to 1.50) | 1.50 (1.00 to 2.00) | 1.50 (0.500 to 2.00) | 1.51 (0.500 to 3.02) | 1.00 (1.00 to 2.00) |
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.
| Hours | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Terminal Half-Life (t1/2) for Plasma Ertugliflozin | 14.62 ± 6.37 | 25.94 ± 13.98 | 22.89 ± 7.35 | 24.17 ± 5.98 | 17.71 ± 3.53 |
VzF is the apparent volume of distribution during terminal phase after oral / extravascular administration. VzF = Dose/(AUCinf × kel) where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Geometric Coefficient of Variation was reported as a percent.
| Liters | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Apparent Volume of Distribution Following Oral Administration (Vz/F) for Plasma Ertugliflozin | 239.7 ± 53 | 254.5 ± 50 | 228.3 ± 27 | 268.8 ± 41 | 304.5 ± 39 |
Fraction of unbound (not protein-bound) drug in plasma. Fu is determined using in vitro equilibrium dialysis method: concentration in buffer at equilibrium/concentration in plasma at equilibrium. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined.
| Percent of Unbound Drug | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Unbound Fraction (Fu) for Plasma Ertugliflozin | 0.03437 ± 0.0011219 | 0.03458 ± 0.0027696 | 0.03804 ± 0.0021287 | 0.04107 ± 0.0036621 | 0.03484 ± 0.0014822 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.
| Milligrams | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) | 0.1494 ± 55 | 0.1081 ± 54 | 0.09682 ± 21 | 0.05843 ± 40 | 0.1231 ± 48 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96% = Ae96 / Dose × 100 Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.
| Percent | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Percent of Dose Recovered Unchanged in Urine From 0 to 96 Hours Postdose (for Ertugliflozin Only) (Ae96%) | 0.9952 ± 55 | 0.7200 ± 54 | 0.6456 ± 21 | 0.3893 ± 40 | 0.8213 ± 48 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.
| mL/min | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Renal Clearance (CLr) for Urinary Ertugliflozin | 2.092 ± 28 | 0.9872 ± 45 | 0.8024 ± 34 | 0.5360 ± 23 | 1.682 ± 33 |
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Participants | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 1 | 2 | 2 | 3 | 4 |
An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Participants | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Number of Participants Who Discontinued Study Due to an AE | 0 | 0 | 0 | 0 | 0 |
Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.
| ng•hr/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 Extrapolated to Infinite Time (AUCinf) | 1559 ± 21 | 2620 ± 34 | 3668 ± 56 | 2742 ± 41 | 1113 ± 32 |
Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.
| ng•hr/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06481944 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) | 1536 ± 21 | 2517 ± 32 | 3552 ± 55 | 2642 ± 40 | 1090 ± 33 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined. Geometric Coefficient of Variation was reported as a percent.
| ng/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06481944 | 217.8 ± 18 | 309.0 ± 30 | 358.5 ± 28 | 218.6 ± 33 | 168.6 ± 34 |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.
| Hours | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06481944 | 2.00 (1.00 to 3.00) | 2.00 (1.50 to 4.00) | 3.00 (1.50 to 3.00) | 3.00 (1.50 to 4.00) | 2.00 (1.50 to 3.00) |
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF 06481944 was determined.
| Hours | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06481944 | 16.68 ± 9.46 | 22.04 ± 12.15 | 23.33 ± 6.15 | 22.83 ± 5.92 | 17.51 ± 5.69 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Geometric Coefficient of Variation was reported as a percent.
| Milligrams | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06481944 | 7.056 ± 32 | 5.861 ± 36 | 3.768 ± 40 | 1.630 ± 41 | 6.225 ± 32 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Geometric Coefficient of Variation was reported as a percent.
| mL/min. | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| CLr for Urinary Glucuronide Metabolite PF-06481944 | 76.28 ± 24 | 38.73 ± 58 | 17.67 ± 56 | 10.27 ± 80 | 94.53 ± 25 |
Area under the plasma concentration-time profile from Time 0 extrapolated to infinite time. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
| ng•hr/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 Extrapolated to Infinite Time (AUCinf) | 383.9 ± 26 | 604.1 ± 39 | 950.9 ± 75 | 975.0 ± 53 | 337.6 ± 27 |
Area under the plasma concentration-time profile from Time 0 to the time of the last quantifiable concentration (Clast). Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
| ng•hr/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile for Glucuronide Metabolite PF-06685948 From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) | 371.9 ± 27 | 579.8 ± 37 | 917.7 ± 74 | 922.1 ± 51 | 329.1 ± 28 |
Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
| ng/mL | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) for Glucuronide Metabolite PF-06685948 | 44.44 ± 22 | 53.56 ± 17 | 63.10 ± 42 | 46.42 ± 35 | 43.90 ± 24 |
Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose and is observed directly from data as time of first occurrence. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.
| Hours | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Time for Cmax (Tmax) for Plasma Glucuronide Metabolite PF-06685948 | 2.00 (1.50 to 3.00) | 3.00 (2.00 to 4.03) | 4.00 (2.00 to 4.00) | 3.51 (3.00 to 4.02) | 2.00 (2.00 to 3.00) |
T1/2 is the time required for a given drug concentration in the plasma to decrease by 50%. T1/2 = Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined.
| Hours | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Terminal Half-life (t1/2) for Plasma Glucuronide Metabolite PF-06685948 | 14.87 ± 7.77 | 21.71 ± 11.26 | 22.49 ± 5.30 | 25.22 ± 10.42 | 15.68 ± 4.66 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. Ae96 = Sum of \[urine concentration × sample volume\] for each collection interval from 0 to 96 hours post dose. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
| Milligrams | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Cumulative Amount of Drug Recovered Unchanged in Urine to 96 Hours Post Dose (Ae96) for Glucuronide Metabolite PF-06685948 | 0.9575 ± 45 | 0.7882 ± 33 | 0.6603 ± 49 | 0.3195 ± 43 | 0.8287 ± 40 |
Urine samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of ertugliflozin was determined. CLr is Renal Clearance (Ae96 / AUC96), where Ae96 is the cumulative amount of drug recovered unchanged in urine to 96 hours post dose and AUC96 was the area under the concentration-time profile form time 0 to 96 hours. Blood samples were taken at pre-dose up to 96 hours post-dose, from which the concentration of glucuronide metabolite PF-06685948 was determined. Geometric Coefficient of Variation was reported as a percent.
| mL/min | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Renal Clearance (CLr) for Urinary Glucuronide Metabolite PF-06685948 | 41.82 ± 24 | 22.50 ± 45 | 11.95 ± 49 | 5.778 ± 43 | 41.42 ± 31 |
Inhibition of Glucose Reabsorption = 100 \* urinary glucose excretion / (eGFR(ML/MIN) \* Weighted Mean Plasma Glucose \* 0.0144). 0.0144 is a unit conversion factor used to make the ratio unitless. Geometric Coefficient of Variation was reported as a percent.
| Percentage | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Change From Baseline in 24 Hour Inhibition of Glucose Reabsorption | 33.34 ± 22 | 25.58 ± 77 | 28.84 ± 34 | 24.25 ± 61 | 29.19 ± 34 |
Fluid balance = fluid intake - urine output.
| Milliliters | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Change From Baseline in 24 Hour Fluid Balance | -660.67 ± 515.48 | -937.00 ± 539.14 | -696.38 ± 832.57 | 111.50 ± 736.79 | -478.63 ± 583.02 |
Participants were asked to void at the end of each prescribed interval with forced voids prior to start and at the end of each interval.
| Grams | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) |
|---|---|---|---|---|---|
| Urinary Glucose Excretion Over 24 Hours (UGE0-24hr) for Ertugliflozin | 72.31 ± 30 | 35.98 ± 113 | 27.55 ± 68 | 10.09 ± 57 | 46.33 ± 31 |
Collected over Up to 19 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T2DM Normal Renal Function | — | 0/6 (0%) | 1/6 (16.7%) |
| T2DM Mild Renal Impairment | — | 0/8 (0%) | 2/8 (25%) |
| T2DM Moderate Renal Impairment | — | 0/8 (0%) | 1/8 (12.5%) |
| T2DM Severe Renal Impairment | — | 0/6 (0%) | 3/6 (50%) |
| Healthy Normal Renal Function | — | 0/8 (0%) | 4/8 (50%) |
| Event | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment | Healthy Normal Renal Function |
|---|---|---|---|---|---|
| HypoglycaemiaMetabolism and nutrition disorders | 0/6 | 1/8 | 0/8 | 2/6 | 0/8 |
| Catheter site erythemaGeneral disorders | 1/6 | 0/8 | 0/8 | 0/6 | 0/8 |
| Dermatitis contactSkin and subcutaneous tissue disorders | 0/6 | 0/8 | 0/8 | 1/6 | 1/8 |
| ConstipationGastrointestinal disorders | 0/6 | 0/8 | 0/8 | 0/6 | 1/8 |
| Vessel puncture site haemorrhageGeneral disorders | 0/6 | 1/8 | 0/8 | 0/6 | 0/8 |
| Urinary tract infectionInfections and infestations | 0/6 | 0/8 | 1/8 | 0/6 | 0/8 |
| Nasal mucosal disorderRespiratory, thoracic and mediastinal disorders | 0/6 | 0/8 | 1/8 | 0/6 | 0/8 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/6 | 0/8 | 0/8 | 0/6 | 1/8 |
| Rash papularSkin and subcutaneous tissue disorders | 0/6 | 0/8 | 0/8 | 0/6 | 1/8 |
Renal function groups were based on body surface area (BSA)-unnormalized estimated glomerular filtration rate (eGFR).
| Age, Continuous(Years) | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) | Total |
|---|---|---|---|---|---|---|
| Mean | 63.2 ± 3.5 | 66.4 ± 2.4 | 65.8 ± 7.9 | 61.2 ± 10.3 | 64.3 ± 3.9 | 64.4 (60 to 76) |
| Sex: Female, Male(Participants) | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 5 | 4 | 0 | 3 | 13 |
| Male | 5 | 3 | 4 | 6 | 5 | 23 |
| Baseline Urinary Glucose Excretion (UGE)(Grams) | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) | Total |
|---|---|---|---|---|---|---|
| Median | 8.2 ± 10.49 | 0.1 ± 10.21 | 0.2 ± 0.93 | 2.3 ± 3.44 | 0.1 ± 0.04 | 1.8 (0.0 to 29.0) |
| Baseline eGFR(mL/min/1.73 m²) | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) | Total |
|---|---|---|---|---|---|---|
| Mean | 92.1 ± 14.10 | 64.7 ± 7.52 | 37.1 ± 6.92 | 17.0 ± 7.51 | 88.5 ± 11.64 | 60.5 (6.8 to 115.0) |
| Baseline Inhibition of Glucose Readsorption(Percentage) | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) | Total |
|---|---|---|---|---|---|---|
| Median | 2.7 ± 3.45 | 0.1 ± 5.17 | 0.3 ± 1.05 | 3.3 ± 19.42 | 0.0 ± 0.02 | 1.1 (0.0 to 50.4) |
| Baseline Fluid Balance(Milliliters) | Ertugliflozin 15 mg (T2DM With Normal Renal Function) | Ertugliflozin 15 mg (T2DM With Mild Renal Impairment) | Ertugliflozin 15 mg (T2DM With Moderate Renal Impairment) | Ertugliflozin 15 mg (T2DM and With Severe Renal Impairment) | Ertugliflozin 15 mg (Healthy Part. With Normal Renal Function) | Total |
|---|---|---|---|---|---|---|
| Median | -644.0 ± 668.11 | -274.8 ± 570.44 | 238.8 ± 763.10 | -267.5 ± 430.85 | -359.5 ± 693.65 | -243.1 (-1780.0 to 1055.0) |
No study locations are listed for this record.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Oct 2013 to primary completion in Oct 2014, 12 months.
Results were first posted in Feb 2019, 4 years 4 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.
Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin